Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity.

Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity. Abstract Text:

Context.-Inflammation is pivotal to atherosclerosis. The monocyte-macrophage, a crucial cell in atherogenesis, is present during all stages of atherosclerosis. However, there is a paucity of data comparing circulating monocytes to cholesterol-laden macrophages (foam cells), with regard to their atherogenic properties, especially in subjects with established risk factors such as hyperlipidemia. Objective.-To determine whether the circulating blood monocyte is representative of the cholesterol-loaded macrophage with regard to its proatherogenicity in healthy controls and hyperlipidemic patients. Design.-Fasting blood was drawn from 32 subjects (n = 16 controls and n = 16 hyperlipidemic patients), and peripheral blood monocytes were obtained. Also, macrophages were cultured and loaded with acetyl low-density lipoprotein on day 10. Day 1 peripheral blood monocytes and day 11 cholesterol-loaded macrophages were assessed for release of superoxide anion and cytokines (interleukin 1, interleukin 6, tumor necrosis factor alpha); surface expression of CD11b, VLA-4, and CD40; and adhesion to human endothelium. Results.-Monocyte and cholesterol-loaded macrophage superoxide anion release, cytokines, and adhesion of monocytes to human endothelium were significantly increased in hyperlipidemic patients compared with controls. Furthermore, following cholesterol loading, there were no significant differences in monocyte versus cholesterol-loaded macrophage activity (P = .71). Also, CD14 and CD11b surface expression on monocytes was significantly increased in hyperlipidemic patients as compared with controls. The magnitude of change in the monocytes versus cholesterol-loaded macrophages was similar. Conclusions.-From these studies, we can conclude that the monocyte, which is readily accessible, is an appropriate cell to study for modulation of proatherogenic activity, especially with regard to genomic and proteomic analyses/ microarrays.

Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Archives of pathology & laboratory medicine

VOLUME: 132

Page Numbers: 1432-5

Journal Abbreviation: Arch. Pathol. Lab. Med.

ISSN: 1543-2165

DAY: 15

MONTH: Sep

YEAR: 2008

Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7607091

Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity.

AFFILIATION:

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Arch Pathol Lab Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity Related Publications

• A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress.
• Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop.
• C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling.
• CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers.
• Contemporary scientific insights: role of biomarkers of inflammation in cardiovascular disease/atherosclerosis.
• Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results.
• Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome.
• Editor's Perspective on Metabolic Syndrome for 2008.
• Editorial.
• Effect of high-dose {alpha}-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease.
• Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome.
• High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy.
• High-fat, energy-dense, fast-food-style breakfast results in an increase in oxidative stress in metabolic syndrome.
• Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats.
• Increased Toll-Like Receptor (TLR) 2 and TLR4 Expression in Monocytes from Patients with Type 1 Diabetes: Further Evidence of a Proinflammatory State.
• Oxidative stress and atherosclerosis.
• RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus.
• Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome.
• Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.
• Statins and biomarkers of inflammation.
• The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells.
• The effect of weight loss and dietary fatty acids on inflammation.
• Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity.